Should remdesivir be recommended in France in the early stage of COVID-19

Abstract

COVID-19 due to SARS-CoV-2, has become a raging pandemic. Remdesivir, an RNA-dependent RNA polymerase (RdRP) inhibitor, was the first antiviral drug to be approved for SARS-CoV-2 in the United States (Beigel et al., 2020) and Europe (European Medicine Agency, 2020) and affects the hospital length of stay but not mortality (Goldman et al., 2020). The Solidarity and Discovery trials did not find a clinical benefit from the use of remdesivir in COVID-19 treatment (Ader et al., 2021, Consortium et al., 2021).